Article Information
History
- February 9, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Michael Di Iorio, MD1,2,
- Claire E. Cook, MPH3,
- Kathleen M.M. Vanni, BA4,
- Naomi J. Patel, MD2,3,
- Kristin M. D’Silva, MD2,3,
- Xiaoqing Fu, MS3,
- Jiaqi Wang, MSc4,
- Lauren C. Prisco, BA4,
- Emily Kowalski, BS4,
- Alessandra Zaccardelli, MS4,
- Lily W. Martin, BS4,
- Grace Qian, BS4,
- Tiffany Y-T. Hsu, MD, PhD2,4,
- Zachary S. Wallace, MD, MSc2,3,5,* and
- Jeffrey A. Sparks, MD, MMSc2,4,*,†
- 1Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
- 2Harvard Medical School, Boston, MA, USA
- 3Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA
- 4Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA
- 5Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- ↵†Correspondence:
Jeffrey A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, 60 Fenwood Road, #6016U, Boston, MA 02115, 617-525-1040, jsparks{at}bwh.harvard.edu, @jeffsparks
↵* JAS and ZSW contributed equally to this work (co-senior authors).
Posted February 09, 2022.
DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study
